Tracing Metabolic Inflexibility in Fanconi Anemia
-
By
-
Henry Thomas
-
February 10, 2026
-
11 min
By
Henry Thomas
February 10, 2026
Going beyond the gut: why microbiome testing is the next big thing in drug development
July 20, 2026
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the bladder cancer clinical updates you need to know from AACR 2026.
June 17, 2026
Dana-Farber Cancer Institute's Dr. Sara Tolaney from the ASCENT-03 stud in breast cancer. The data further strengthens the case for approval of sacituzumab govitecan as first-line treatment for patients with advanced triple-negative breast cancer.
July 1, 2026